1. Introduction {#sec1-ijerph-16-04426}
===============

Charcoal burning suicide is a serious public health problem in Asia. Since the first case of suicide by burning charcoal in 1998 in Hong Kong, cases have increased in many Far East areas, such as Taiwan, Japan, Korea, and China. In Taiwan, 32 people committed suicide by burning charcoal in 1998, but 1346 cases were noted in 2005 \[[@B1-ijerph-16-04426]\]. This endemic of charcoal burning suicide was thought to be promoted by media because this way of suicide is always described as painless and easy \[[@B2-ijerph-16-04426]\]. In Taiwan, the number of charcoal burning suicide attempts was the second biggest method of all suicides, and comprised 33.5% of all suicide related deaths \[[@B3-ijerph-16-04426]\].

Carbon monoxide (CO) poisoning is the main cause of mortality and morbidity after charcoal burning suicide. The most common brain lesion is globus pallidus necrosis \[[@B4-ijerph-16-04426],[@B5-ijerph-16-04426]\]. Symmetric hypodensity over globus pallidus can be found in computed tomography (CT). The medial portion of the globus pallidus shows low intensity on T1-weighted images but high intensity on T2-weighted images on magnetic resonance imaging (MRI) \[[@B6-ijerph-16-04426]\]. The pathophysiology of globus pallidus necrosis remains unclear. One study revealed that learning and memory deficit was noted in rats exposed to CO, and there were higher glutamate and hydroxide levels in these rats \[[@B7-ijerph-16-04426]\]. Another study noted a hypotensive effect in the watershed territory of the arterial supply and hypoxia due to decreased arterial supplement or CO binding to globus pallidus, which is an iron-rich area \[[@B6-ijerph-16-04426]\]. Hypotension or shock status either due to sepsis, metabolic acidosis, or myocardial infarction could contribute to poorer brain perfusion. Because of the higher affinity of CO to hemoglobin over oxygen, this hypoxic effect can be systemic and produces multi-organ failure \[[@B8-ijerph-16-04426]\].

Risk factors for mortality after CO poisoning have been reported in the literature. Hypothermia, respiratory failure, renal failure, or coma indicates poor prognosis \[[@B9-ijerph-16-04426]\]. Acute kidney injury has been revealed as another risk factor for short-term mortality after charcoal burning suicide \[[@B8-ijerph-16-04426]\]. However, few reports have analyzed the outcomes of charcoal burning suicide in the context of globus pallidus necrosis. Therefore, the objective of this study was to examine predictors of globus pallidus necrosis in this charcoal burning population.

2. Methods {#sec2-ijerph-16-04426}
==========

This retrospective observational study followed the Declaration of Helsinki and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital (Institutional Review Board code number: 201701109B0).

2.1. Patients {#sec2dot1-ijerph-16-04426}
-------------

Between 2002 and 2013, a total of 67 patients who had attempted charcoal burning suicide were admitted to Chang Gung Memorial hospital, Linkou, Taiwan. All patients received psychiatric consultation-liaison services. Demographic data such as age, gender, underlying disease, personal habits, and previous suicide attempt history were recorded. Clinical data such as fever, acute respiratory failure, acute myocardial infarction, acute hepatic injury, acute kidney injury, rhabdomyolysis, neuropsychiatric symptoms, stroke, shock, out-of-hospital cardiac arrest, etc. were analyzed. Laboratory data such as blood tests and radiographic examinations were obtained. The carboxyhemoglobin levels were measured at admission. Treatment modalities such as oxygen therapy, hyperbaric oxygen therapy, and mortality were collected.

2.2. Oxygen Therapy {#sec2dot2-ijerph-16-04426}
-------------------

None of the patients received oxygen therapy prior to admission. After admission, patients were treated with oxygen therapy via a non-rebreather facemask or hyperbaric oxygen (HBO) therapy. There was no standard indication for HBO treatment \[[@B8-ijerph-16-04426]\]. Nevertheless, the absolute contraindication for HBO was an untreated pneumothorax. Moreover, the relative contraindications comprised asthma, chronic obstructive pulmonary disease, seizure, fever, active infection, active malignancy, claustrophobia, pregnancy, and patients who needed intensive medical care \[[@B8-ijerph-16-04426]\].

2.3. Inclusion and Exclusion Criteria {#sec2dot3-ijerph-16-04426}
-------------------------------------

All patients who had attempted charcoal burning suicide and had received brain image analysis were enrolled into this study, but patients with CO intoxication due to other etiologies were excluded from the analysis. There was no routine use of brain imaging to aid in the clinical management of patients, but 67 out of 126 patients received brain image analysis.

2.4. Definition of Globus Pallidus Necrosis {#sec2dot4-ijerph-16-04426}
-------------------------------------------

The diagnosis of globus pallidus necrosis was confirmed by radiographic imaging studies. The typical findings were low intensity on T1-weighted images but high intensity on T2-weighted images over the bilateral globus pallidus area in MRI, or symmetric hypodensity over globus pallidus in CT.

2.5. Definition of Neuropsychiatric Symptoms {#sec2dot5-ijerph-16-04426}
--------------------------------------------

Neuropsychiatric symptoms were defined as a new onset of cognitive and personality changes, dementia, psychosis, Parkinsonism, amnesia, depression, and incontinence after charcoal burning suicide.

2.6. Statistical Analysis {#sec2dot6-ijerph-16-04426}
-------------------------

Normality of distribution and equality of standard deviation was tested in all variables before analysis. Continuous variables were expressed as means ± standard deviations whereas categorical variables were expressed as numbers (percentages). Non-normal distribution data were presented as median (interquartile range). Comparisons between two groups were performed using the Student's T test for continuous variables and the Chi-square or Fisher's exact test for categorical variables. A univariable logistic regression analysis was performed to compare the frequency of possible risk factors associated with globus pallidus necrosis. To control for confounding factors, a multivariable logistic regression analyses was performed to analyze the significant factors on univariable analysis that met the assumptions of a proportional hazard model. All statistical tests were two-tailed, with *p* values \<0.05 being considered statistically significant. Data were analyzed with IBM SPSS Statistics Version 20 (IBM Corporation, Armonk, NY, USA).

3. Results {#sec3-ijerph-16-04426}
==========

[Table 1](#ijerph-16-04426-t001){ref-type="table"} describes the baseline demographic characteristics of 67 patients who had attempted charcoal burning suicide, stratified according to either presence (*n* = 40) or absence (*n* = 27) of globus pallidus necrosis. The patients aged 36.8 ± 11.1 years (67.2%) were male. It was found that patients with globus pallidus necrosis were younger (34.5 ± 9.6 vs. 40.1 ± 12.4, *p* = 0.044) and had less hypertension (2.5% vs. 22.2%, *p* = 0.015) than patients without globus pallidus necrosis. Otherwise, there were no significant differences in other baseline variables (*p* \> 0.05).

As shown in [Table 1](#ijerph-16-04426-t001){ref-type="table"}, patients with globus pallidus necrosis suffered from severer medical complications when they were admitted to the hospital, i.e., fever (47.5% vs. 14.8%, *p* = 0.008), acute myocardial injury (52.5% vs. 22.2%, *p* = 0.022), acute rhabdomyolysis (52.5% vs. 22.2%, *p* = 0.022) and neuropsychiatric symptoms (70.0% vs. 22.2%, *p* \< 0.001) than patients without globus pallidus necrosis. Additionally, patients with globus pallidus necrosis had poorer blood test results, i.e., aspartate transaminase (119 U/L vs. 39.0 U/L, *p* = 0.001), creatinine kinase (4610 U/L vs. 303 U/L, *p* = 0.020), creatine kinase--MB (19.2 U/L vs. 4.1 U/L, *p* = 0.014), creatinine (1.37 mg/dL vs. 0.9 mg/dL, *p* = 0.022), troponin I (1.73 vs. 0.14, *p* \< 0.001), and bicarbonate (19.1 ± 4.5 mg/dL vs. 22.1 ± 4.1 mg/dL, *p* = 0.007) than patients without globus pallidus necrosis. However, there was no significant difference in blood carboxyhemoglobin levels between both groups (18.4% ± 3.2% vs. 26.7% ± 3.5%, *p* = 0.086). All patients received oxygen therapy using non-rebreather facemasks. Nevertheless, patients with globus pallidus necrosis received less hyperbaric oxygen therapy than patients without globus pallidus necrosis (30.0% vs. 59.3%, *p* = 0.024).

The results of univariable and multivariable logistic regression analysis are shown in [Table 2](#ijerph-16-04426-t002){ref-type="table"} and [Table 3](#ijerph-16-04426-t003){ref-type="table"}. In a multivariable regression model ([Table 3](#ijerph-16-04426-t003){ref-type="table"}), it was disclosed that acute myocardial injury (odds ratio 4.6, confidence interval 1.1--18.9, *p* = 0.034) and neuropsychiatric symptoms (odds ratio 8.0, confidence interval 2.0--31.4, *p* = 0.003) were significant risk factors for globus pallidus necrosis. In contrast, bicarbonate level (odds ratio 0.8, confidence interval 0.7--1.0, *p* = 0.032), and age (odds ratio 0.9, confidence interval 0.9--1.0, *p* = 0.038) were protective factors associated with lower risk of globus pallidus necrosis.

4. Discussion {#sec4-ijerph-16-04426}
=============

Our analytical data ([Table 1](#ijerph-16-04426-t001){ref-type="table"}) revealed that although patients who had attempted charcoal burning suicide had a low mortality rate (3.0%), globus pallidus necrosis was not uncommon (59.7%). There were some studies in the literature that had discussed the relationship between CO intoxication and globus pallidus necrosis ([Table 4](#ijerph-16-04426-t004){ref-type="table"}). Most of the studies were from Asian countries, and the incidence rates of globus pallidus necrosis after CO intoxication ranged between 18.7% and 100% \[[@B4-ijerph-16-04426],[@B10-ijerph-16-04426],[@B11-ijerph-16-04426],[@B12-ijerph-16-04426],[@B13-ijerph-16-04426],[@B14-ijerph-16-04426],[@B15-ijerph-16-04426],[@B16-ijerph-16-04426],[@B17-ijerph-16-04426],[@B18-ijerph-16-04426],[@B19-ijerph-16-04426],[@B20-ijerph-16-04426]\]. Nevertheless, the sources of CO were not mentioned in many of the studies. A large registry-based study from Korea \[[@B11-ijerph-16-04426]\] revealed that globus pallidus necrosis developed in 19.9% of patients, but the source of CO was not described, and the mortality rate was not reported. Another Korean study \[[@B12-ijerph-16-04426]\] in patients with charcoal burning reported an 18.7% rate of globus pallidus necrosis and a 0% mortality rate. Compared with the above two studies, it seemed that our patients suffered a higher incidence rate of globus pallidus necrosis (59.7%) and had a slightly higher mortality rate (3.0%).

A total of 56.7% patients had mood disorder, and 19.4% has past suicide attempt history ([Table 1](#ijerph-16-04426-t001){ref-type="table"}). Chronic alcohol consumption (49.3%) and a smoking habit (55.2%) were noted in approximately half of patients. This characteristic of charcoal burning suicide patients was similar to other studies based in Korea, Hong Kong, and Japan \[[@B21-ijerph-16-04426],[@B22-ijerph-16-04426],[@B23-ijerph-16-04426],[@B24-ijerph-16-04426]\]. An increasing trend in charcoal burning suicide was noted in Asian countries \[[@B23-ijerph-16-04426]\]. Mass media reporting plays an important role in the increased incidences of charcoal burning suicides \[[@B25-ijerph-16-04426],[@B26-ijerph-16-04426],[@B27-ijerph-16-04426]\]. The higher incidence rate is believed to be due to the traditional perception of the ethnic Chinese group who believe that a person should die with a complete body. The media portrayal of charcoal burning suicide as painless and easy, with no body disfigurement, contributes to the rapid spread of news in the era of globalization.

In a multivariable regression model ([Table 4](#ijerph-16-04426-t004){ref-type="table"}), it was noted that neuropsychiatric symptoms (*p* = 0.003) and acute myocardial injury (*p* = 0.034) were powerful predictors of globus pallidus necrosis. Reduction of oxygen delivery along with mitochondrial oxidative phosphorylation could lead to ischemic and hypoxic brain injury in CO intoxication patients \[[@B28-ijerph-16-04426]\]. These patients commonly have neurologic symptom that include headache, dizziness, loss of consciousness, nausea, vomiting, etc. \[[@B29-ijerph-16-04426]\]. Delayed neurologic sequels, like depression, anxiety, memory symptoms, and motor deficits were also reported \[[@B29-ijerph-16-04426]\]. The incidence rate of neuropsychiatric symptoms in our study was 50.7% in all patients and was higher in patients with globus pallidus necrosis (70.0%, [Table 1](#ijerph-16-04426-t001){ref-type="table"}). According to a study \[[@B11-ijerph-16-04426]\], the incidence rate of globus pallidus lesions in CO intoxication patients was 19.9%, less than the 59.7% in our study. The percentage of delayed neurologic sequel was not different between the presence and absence of globus pallidus lesion (78.6% vs. 72.4%) \[[@B11-ijerph-16-04426]\]. Another study from Hong-Kong revealed that delayed neurologic sequel happened in 7.5% of patients with CO poisoning but 57.1% in the subgroup with globus pallidus lesions \[[@B30-ijerph-16-04426]\]. Therefore, the relationship between globus pallidus necrosis and acute neuropsychiatric symptoms or delayed neurologic sequel remains unclear and needs more study to evaluate their correlation.

There are some case reports noted about the correlation between acute myocardial injury and globus pallidus necrosis \[[@B25-ijerph-16-04426],[@B31-ijerph-16-04426],[@B32-ijerph-16-04426]\]. Only one registry-based cohort study showed that patients with CO poisoning have a higher risk of major adverse cardiovascular events \[[@B33-ijerph-16-04426]\]. The incidence rate of acute myocardial injury was 40.3% in our study ([Table 1](#ijerph-16-04426-t001){ref-type="table"}). Furthermore, patients with globus pallidus necrosis suffered a higher rate of acute myocardial injury than patients without globus pallidus necrosis (52.5% vs. 22.2%, *p* = 0.022). To our knowledge, there is a 200 times greater affinity of carbon monoxide to hemoglobin then to oxygen, so the human body would suffer from hypoxia damage in patients who had attempted suicide by charcoal burning. The organs affected the most by carbon monoxide are the central nervous system and the myocardium, whose organs need oxygen the most. The patients with globus pallidus necrosis were affected more by hypoxia, so these patients would also have myocardium injury. Also, a decrease in oxygen delivery would increase global oxygen demand and myocardial contractility, which would induce myocardial infarction in patients with underlying coronary artery disease \[[@B34-ijerph-16-04426]\]. Hypertension appeared to be a protective factor of globus pallidus necrosis in our study. While an elevation of blood pressure was noted, the increased blood perfusion for all organs, especially the brain, was also noted. Therefore, less hypoxia episodes, as well as globus pallidus necrosis, will be seen in the hypertension status. In support of this concept, a forensic pathology study \[[@B35-ijerph-16-04426]\] also indicated that globus pallidus necrosis is merely a consequence of cerebral hypoxia--ischemia from a wide variety of etiologies such as drug overdose, post-anesthesia, in children after cardiac surgery, hemolytic uremic syndrome, acute renal failure, metabolic disorders, viral infections, porphyria and cerebral arteriosclerosis, delayed hanging, and wasp stings, and it is not specific to any kind of injury.

HBO therapy is a reasonable therapy in acute CO poisoning. The mechanism involves increased oxygen content in the blood, so as to enhance the clearance of CO and to prevent hypoxemic brain injury. In our study, only 41.8% of patient who had attempted charcoal burning suicide received HBO therapy, and the figure was lower (30.0%) in patients with globus pallidus necrosis ([Table 1](#ijerph-16-04426-t001){ref-type="table"}). Previous studies also revealed that only 41.6% of patients who had attempted charcoal burning suicide \[[@B8-ijerph-16-04426]\] and 18.8% of patients with carbon monoxide poisoning \[[@B9-ijerph-16-04426]\] received HBO treatment. The correlation between HBO therapy with mortality was undetermined, and so far there is a lack of standard indication for HBO therapy. One retrospective study from the Nationwide Poisoning Database in Taiwan revealed a lower mortality rate in patients who received HBO therapy \[[@B36-ijerph-16-04426]\]. A single center retrospective study in Pittsburgh revealed that hyperbaric oxygen was associated with reduced acute and reduced one-year mortality \[[@B37-ijerph-16-04426]\]. However, no literature evidence indicates whether HBO therapy could improve globus pallidus necrosis or not. Although the percentage of HBO therapy was lower in our patients with globus pallidus necrosis (30.0%) than in patients without globus pallidus necrosis (59.3%, [Table 1](#ijerph-16-04426-t001){ref-type="table"}), HBO was not a significant predictor for globus pallidus necrosis after multivariable logistic regression analysis ([Table 3](#ijerph-16-04426-t003){ref-type="table"}). Nevertheless, this analysis is limited by the lack of standard indication for HBO.

According to multivariable regression analysis, elevated blood bicarbonate level (*p* = 0.032) and older age (*p* = 0.038) were associated with reduced incidence rate of globus pallidus necrosis. The inverse association between serum bicarbonate concentration and globus pallidus necrosis was not surprising, because those patients with globus pallidus necrosis also suffered from severer medical complications that could induce a greater degree of metabolic acidosis. Nevertheless, there was no clear explanation for the reciprocal relationship between age and globus pallidus necrosis.

5. Conclusions {#sec5-ijerph-16-04426}
==============

Although patients who had attempted charcoal burning suicide had a low mortality rate (3.0%), globus pallidus necrosis was not uncommon (59.7%) in this population. Acute myocardial injury and neuropsychiatric symptoms were associated with an increased risk of globus pallidus necrosis. On the other hands, higher blood bicarbonate levels and older age were associated with a decreased risk of globus pallidus necrosis. Therefore, prompt diagnosis of risk factors and the use of HBO could possibly alter the clinical course of the disease and prevent the development of serious neurologic complications. Nevertheless, this study was limited by its retrospective nature, small sample size, and short follow-up duration. Furthermore, inclusion of patients was based on cerebral imaging, but there was no standard for this. This could have introduced bias. Further studies are warranted.
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###### 

Clinical data of patients who had attempted charcoal burning suicide, stratified by either presence or absence of globus pallidus necrosis (*n* = 67).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                        All Patients (*n* = 67)   Patients with Globus Pallidus Necrosis (*n* = 40)   Patients without Globus Pallidus Necrosis (*n* = 27)   *p* Value
  ---------------------------------------------------------------- ------------------------- --------------------------------------------------- ------------------------------------------------------ ----------------
  Demographics                                                                                                                                                                                          

   Age, year                                                       36.8 ± 11.1               34.5 ± 9.6                                          40.1 ± 12.4                                            0.044 \*

   Male, *n* (%)                                                   45 (67.2)                 25 (62.5)                                           20 (74.1)                                              0.428

   Hypertension, *n* (%)                                           7 (10.4)                  1 (2.5)                                             6 (22.2)                                               0.015 \*

   Diabetes mellitus, *n* (%)                                      6 (9.0)                   2 (5.0)                                             4 (14.8)                                               0.211

   Hepatitis B or C virus carrier, *n* (%)                         6 (9.0)                   3 (7.5)                                             3 (11.1)                                               0.679

   Liver cirrhosis                                                 1 (1.5)                   0 (0)                                               1 (3.7)                                                0.403

   Smoking habit, *n* (%)                                          37 (55.2)                 21 (52.5)                                           16 (59.3)                                              0.796

   Chronic alcohol consumption, *n* (%)                            33 (49.3)                 19 (47.5)                                           14 (51.9)                                              0.885

   Past suicide history, *n* (%)                                   13 (19.4)                 7 (17.5)                                            6 (22.2)                                               0.647

   Mood disorder, *n* (%)                                          38 (56.7)                 23 (57.5)                                           15 (55.6)                                              0.670

   Adjustment disorder, *n* (%)                                    25 (37.3)                 14 (35.0)                                           11 (40.7)                                              0.797

  Clinical manifestations                                                                                                                                                                               

   Systolic blood pressure, mmHg                                   115.6 ± 32.4              113.0 ± 31.8                                        119.4 ± 23.7                                           0.403

   Heart rate, per minute                                          97.6 ± 23.4               101.9 ± 21.0                                        91.2 ± 21.3                                            0.066

   Fever, *n* (%)                                                  23 (34.3)                 19 (47.5)                                           4 (14.8)                                               0.008 \*\*

   Acute respiratory failure, *n* (%)                              27 (40.3)                 20 (50.0)                                           7 (25.9)                                               0.075

   Acute myocardial infarction, *n* (%)                            27 (40.3)                 21 (52.5)                                           6 (22.2)                                               0.022 \*

   Acute hepatic injury, *n* (%)                                   29 (43.3)                 21 (52.5)                                           8 (29.6)                                               0.081

   Acute kidney injury, *n* (%)                                    29 (43.3)                 20 (50.0)                                           9 (33.3)                                               0.214

   Acute rhabdomyolysis, *n* (%)                                   27 (40.3)                 21 (52.5)                                           6 (22.2)                                               0.022 \*

   Neuropsychiatric symptoms, *n* (%)                              34 (50.7)                 28 (70.0)                                           6 (22.2)                                               \<0.001 \*\*\*

   Stroke, *n* (%)                                                 8 (11.9)                  7 (17.5)                                            1 (3.7)                                                0.103

   Shock, *n* (%)                                                  7 (10.4)                  5 (12.5)                                            2 (7.4)                                                0.693

   Out-of-hospital cardiac arrest, *n* (%)                         2 (3.0)                   2 (22.2)                                            0 (0)                                                  0.512

  Laboratory findings (normal range)                                                                                                                                                                    

   Carboxyhemoglobin, % (nonsmoker 0.5--1.5, smoker 4--9)          21.8 ± 19.3               18.4 ± 3.2                                          26.7 ± 3.5                                             0.086

   Blood urea nitrogen, mg/dL (6--21)                              18 (10.0, 20.9)           19.9 (10.6, 23.3)                                   15 (9.0, 20.9)                                         0.164

   Creatinine, mg/dL (M 0.64--1.27, F 0.44--1.03)                  1.20 (0.8, 1.6)           1.4 (0.9, 2.1)                                      0.9 (0.8, 1.5)                                         0.022 \*

   Calcium, mg/dL (7.9--9.9)                                       8.1 ± 0.5                 8.0 ± 0.6                                           8.2 ± 0.4                                              0.111

   Phosphate, mg/dL (2.4--4.7)                                     3.3 ± 0.7                 3.4 ± 0.8                                           3.3 ± 0.5                                              0.722

   Sodium, mEq/L (134--148)                                        141.6 ± 3.1               141.8 ± 3.3                                         141.4 ± 2.9                                            0.613

   Potassium, mEq/L (3.6--5.0)                                     4.2 ± 0.8                 4.3 ± 0.8                                           4.1 ± 0.7                                              0.279

   Albumin, g/dL (3.5--5.5)                                        3.4 ± 0.6                 3.4 ± 0.4                                           3.4 ± 0.8                                              0.988

   Aspartate transaminase, U/L (≤34)                               75.0 (30.0, 196.1)        119.0 (55.3, 206.8)                                 39.0 (21.0, 150.0)                                     0.001 \*\*

   Alanine transaminase, U/L (≤36)                                 58.0 (26.5, 102.0)        77.0 (41.0, 104.0)                                  42.0 (17.3, 98.3)                                      0.080

   Alkaline phosphatase, U/L (36--122)                             60.2 ± 30.6               48.5 ± 3.7                                          76.3 ± 14.5                                            0.101

   Bilirubin total mg/dL (≤1.3)                                    0.7 ± 0.3                 0.8 ± 0.2                                           0.6 ± 0.4                                              0.479

   Troponin I, ng/mL (\<0.4)                                       0.9 (0.2, 2.8)            1.7 (0.6, 5.9)                                      0.1 (0.0, 0.8)                                         \<0.001 \*\*\*

   Creatine kinase, U/L\                                           2029.0 (238.0, 7227.0)    4610.0 (504.5, 13704.0)                             303.0 (100.3, 2164.0)                                  0.020 \*
  (M 20--200, F 20--180)                                                                                                                                                                                

   Creatine kinase-MB, U/L (0.6--6.3)                              11.9 (3.7, 28.5)          19.2 (8.8, 30.5)                                    4.1 (0.8, 12.5)                                        0.014 \*

   Myoglobin, ng/mL\                                               370.7 (180.6, 386.7)      386.7 (96.7, 1023.2)                                41.8 (19.9, 166.1)                                     0.061
  (M 17.4--105.7, F 14.3--65.8)                                                                                                                                                                         

   Hemoglobin, g/dL\                                               14.7 ± 2.2                14.6 ± 2.4                                          14.8 ± 2.0                                             0.800
  (M 13.5--17.5, F 12--16)                                                                                                                                                                              

   White blood cell count, 10^3^/uL\                               15.982 ± 8.064            16.592 ± 1.241                                      15.077 ± 1.624                                         0.455
  (M 3.9--10.6, F 3.5--11.0)                                                                                                                                                                            

   Polymorphonuclear neutrophil, % (42--77)                        81.6 ± 13.1               82.7 ± 13.7                                         80.0 ± 12.2                                            0.417

   Platelet cell count, 10^3^/uL (150--400)                        227.9 ± 71.2              228.7 ± 68.9                                        226.8 ± 75.7                                           0.917

   C-reactive Protein, mg/L (\<5)                                  29.2 (15.1, 74.2)         29.2 (13.8, 80.3)                                   27.6 (14.8 81.8)                                       0.897

  Arterial blood gas                                                                                                                                                                                    

   pH (M 7.34--7.44, F 7.35--7.45)                                 7.37 ± 0.11               7.35 ± 0.13                                         7.40 ± 0.07                                            0.061

   Partial pressure of carbon dioxide, mmHg (M 35--45, F 32--42)   35.1 ± 6.7                34.5 ± 6.4                                          36.0 ± 7.1                                             0.375

   Partial pressure of oxygen, mmHg (75--100)                      241.1 ± 146.4             235.7 ± 25.4                                        249.0 ± 24.0                                           0.706

   Bicarbonate, mmol/L\                                            20.3 ± 4.5                19.1 ± 4.5                                          22.1 ± 4.1                                             0.007 \*\*
  (M 22--26, F 20--24)                                                                                                                                                                                  

  Treatment and outcomes                                                                                                                                                                                

   Oxygen therapy using non-rebreather facemask, *n* (%)           67 (100.0)                40 (100.0)                                          27 (100.0)                                             1.000

   Hyperbaric oxygen therapy, *n* (%)                              28 (41.8)                 12 (30.0)                                           16 (59.3)                                              0.024 \*

   Mortality, *n* (%)                                              2 (3.0)                   2 (22.2)                                            0                                                      0.512
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: F, female; M, male. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001. Continuous variables are expressed as means ± standard deviations whereas categorical variables are expressed as numbers (percentages). Non-normal distribution data were presented as median (interquartile range).
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###### 

Univariable logistic regression analysis of predictors for globus pallidus necrosis (*n* = 67).

  Variable                                           Odds Ratio (95% Confidence Interval)   *p* Value
  -------------------------------------------------- -------------------------------------- ----------------
  Acute myocardial injury (yes)                      3.9 (1.3--11.6)                        0.016 \*
  Neuropsychiatric symptoms (yes)                    8.2 (2.6--25.3)                        \<0.001 \*\*\*
  Bicarbonate level (each increment of 1 mmol/L)     0.8 (0.7--1.0)                         0.010 \*
  Age (each increase of 1 year)                      1.0 (0.9--1.0)                         0.050 \*
  Acute rhabdomyolysis (yes)                         3.9 (1.3--11.6)                        0.016 \*
  Hyperbaric oxygen therapy (yes)                    0.3 (0.1--0.8)                         0.019 \*
  Creatinine level (each increment of 1 mg/dL)       2.8 (1.0--7.6)                         0.044 \*
  Fever (yes)                                        5.2 (1.5--17.8)                        0.009 \*\*
  Hypertension (yes)                                 0.1 (0.0--0.8)                         0.030 \*
  Aspartate transaminase (each increment of 1 U/L)   1.0 (1.0--1.0)                         0.021 \*

Note: \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Multivariable logistic regression analysis of predictors for globus pallidus necrosis (*n* = 67).

  Variable                                         Odds Ratio (95% Confidence Interval)   *p* Value
  ------------------------------------------------ -------------------------------------- ------------
  Acute myocardial injury (yes)                    4.6 (1.1--18.9)                        0.034 \*
  Neuropsychiatric symptoms (yes)                  8.0 (2.0--31.4)                        0.003 \*\*
  Bicarbonate level (each increment of 1 mmol/L)   0.8 (0.7--1.0)                         0.032 \*
  Age (each increment of 1 year)                   0.9 (0.9--1.0)                         0.038 \*

Note: \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Comparison of outcomes between current and published studies (sample size ≥5) from different geographic areas.

  Study                                          Year   Country   Source of Carbon Monoxide   Sample Size   Incidence Rate of Globus Pallidus Necrosis, %                   Mortality Rate, %
  ---------------------------------------------- ------ --------- --------------------------- ------------- --------------------------------------------------------------- -------------------
  Current study                                  2019   Taiwan    Charcoal burning            67            59.7                                                            3.0%
  Jeon et al. \[[@B11-ijerph-16-04426]\]         2018   Korea     Not mentioned               387           19.9                                                            Not mentioned
  Moon et al. \[[@B12-ijerph-16-04426]\]         2018   Korea     Charcoal burning            128           18.7                                                            0%
  Kim et al. \[[@B10-ijerph-16-04426]\]          2017   Korea     Not mentioned               7             100.0                                                           Not mentioned
  Chen et al. \[[@B13-ijerph-16-04426]\]         2013   Taiwan    Charcoal burning            47            25.5                                                            Not mentioned
  Chen et al. \[[@B14-ijerph-16-04426]\]         2013   Taiwan    Not mentioned               30            53.0                                                            Not mentioned
  Chen et al. \[[@B15-ijerph-16-04426]\]         2005   China     Not mentioned               46            82.1 (magnetic resonance imaging); 43.2 (computed tomography)   Not mentioned
  Durak et al. \[[@B16-ijerph-16-04426]\]        2005   Turkey    Not mentioned               8             37.5                                                            Not mentioned
  Kim et al. \[[@B17-ijerph-16-04426]\]          2003   Korea     Not mentioned               5             100.0                                                           Not mentioned
  O'Donnell et al. \[[@B4-ijerph-16-04426]\]     1999   UK        Not mentioned               19            63.2                                                            21.1%
  Matsushita et al. \[[@B18-ijerph-16-04426]\]   1996   Japan     Not mentioned               13            38.4                                                            Not mentioned
  Jones et al. \[[@B19-ijerph-16-04426]\]        1994   USA       Not mentioned               19            36.8                                                            1.0%
  Chang et al. \[[@B20-ijerph-16-04426]\]        1992   Korea     Not mentioned               15            60.0                                                            Not mentioned
